Schizophrenia Medication Study
NAMI is committed to ensuring that the most effective treatments for mental illness are available to those who need them. Determining which treatments are most effective requires research. When NAMI learns of new studies by physicians and other scientists involving new treatment methods, such as psychotherapies, medications, methods of medication delivery, etc. we become excited. That excitement comes from knowing that scientists continue to learn more about mental illness and look for ways to improve the lives of those affected by it. When NAMI is approached to be involved in research of any type, at any level, we take it very seriously.
NAMI’s medical director, Dr. Ken Duckworth and Director of Information & Support Dr. Teri Brister thoroughly review the research protocols and methodology and the documentation that the study has been approved an Institutional Review Board (IRB) to assure the safety of those involved. NAMI does not accept financial compensation for recruiting clinical trial participants. NAMI also does not endorse any products or treatments. We share these research opportunity notices with you, our field leaders, to distribute at your discretion if you believe that members of your community may be interested in participating in these trials. If you have questions about research at NAMI, please email firstname.lastname@example.org.
WHAT IS THE STUDY?
This study is looking at whether a medication called brexpiprazole is safe and effective in reducing the symptoms of schizophrenia in youth aged 13-17. Brexpiprazole has already been approved by the FDA to treat symptoms of schizophrenia in adults. The goal of this study is to increase treatment options for youth with schizophrenia.
WHO CAN PARTICIPATE?
Participants may be eligible for this study if they:
- Are 13-17 years old
- Have a current, confirmed diagnosis of schizophrenia
- Have experienced symptoms of schizophrenia for at least 6 months prior to joining the study
There will be approximately 400 people participating in this study world-wide.
WHERE IS THE STUDY TAKING PLACE?
This study will take place at approximately 45 clinic sites across the USA. Please visit the study website to view clinic sites in your region.
HOW DO I LEARN MORE?
If you have questions or would like more information, please refer to the study website